ORION CORPORATION STOCK EXCHANGE RELEASE 19 JULY 2017 at 11.00 A.M. EEST
Orion Corporation's financial reporting and Annual General Meeting in 2018
Orion Corporation will publish its Financial Statement Release 2017 on Wednesday, 7 February 2018.
The publication dates of the Interim Reports and the Half-Year Financial Report in 2018 are as follows:
| Interim Report January-March 2018 |
Half-Year Financial Report January-June 2018
Interim Report January-September 2018
| Tuesday , 24 April 2018 |
Wednesday, 18 July 2018
Wednesday, 24 October 2018
The Financial Statements and the report of the Board of Directors for 2017 will be published on the Company's website at the latest in week 9/2018.
The Annual General Meeting is planned to be held on Tuesday, 20 March 2018 in Helsinki.
Orion's financial reports and related presentation material are available on the Group's website at http://www.orion.fi/investors promptly after the publishing. The website also provides a possibility to register on Orion's mailing lists for releases.
| Timo Lappalainen |
President and CEO
| Olli Huotari |
SVP, Corporate Functions
Lilli Riikonen, Communications Manager, tel. +358 10 426 2319
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.